Proposed adoption of the 2024 H share option plan
Voluntary Announcement - Data from the M701 Phase II study of Malignant Ascites presented at the 2024 ASCO Meeting
Monthly Return of equity Issuer on movements in Securities for the month ended 30 April 2024
List of directors and their roles and functions
Resignation of non-executive director
2023 Environmental, Social and Governance Report
Annual Report 2023
Monthly Return of equity Issuer on movements in Securities for the month ended 31 March 2024
Annual Results Announcement for the year ended 31 December 2023
Voluntary Announcement - The first patient was enrolled in the Phase III clinical trial of bisspecific antibody M701 malignant ascites